Bronchial Biopsy Devices Market Size, Share, Trends, Companies and Forecast 2026 to 2035

Revenue, 2026

USD 777.02 Mn

Forecast Year, 2035

USD 1,468.35 Mn

CAGR, 2026 - 2035

7.34%

Report Coverage

Global

What is the Bronchial Biopsy Devices Market Size?

The global bronchial biopsy devices market size is calculated at USD 777.02 million in 2026 and is predicted to reach approximately USD 1,468.35 million by 2035, expanding at a CAGR of 7.34% from 2026 to 2035. The bronchial biopsy devices market is growing because of the rising incidence of respiratory illnesses and lung cancer, as well as improved technologies, an increasing number of elderly, and growing awareness of people towards health, which also contributes to growth in demand.

Bronchial Biopsy Devices Market Key Takeaways

• In terms of revenue, the global bronchial biopsy devices market was valued at USD 723.35 million in 2025.
• It is projected to reach USD 1,468.35 million by 2035.
• The market is expected to grow at a CAGR of 7.34% from 2026 to 2035.
• North America dominated the global market, accounting for the largest market share in 2025.
• Asia Pacific is expected to grow at the fastest CAGR during the forecast period.
• The TBNA needles segment accounted for the largest product share in 2025..
• By product, the biopsy forceps product segment is expected to grow at a notable CAGR during the forecast period.

Market Overview

A biopsy is defined as a medical operation carried out to remove tissues from an organ to determine the existence of a disease, specifically inflammatory and neoplastic diseases. Lung Biopsy is the extraction of the lung tissues to diagnose any lung disease, infection, or cancer. Increased incidence of cancer, especially the breast, prostate, and lung, coupled with increased technological development in biopsy, has propelled the bronchial biopsy devices market. Bronchoscopic biopsy may be used to obtain tissue samples for definitive diagnosis and characterization of selected pulmonary diseases, including lung cancer and certain interstitial or endobronchial disorders.

The constantly rising incidence of lung diseases requires new diagnostic tools. The cases of respiratory diseases such as lung cancer and interstitial lung disease are on the rise worldwide, and there is a need for prompt and accurate lung biopsies. This diagnostic procedure is necessary for determining the presence, extent, and nature of lung diseases, posing insights that are crucial for effective treatment planning.

How is AI Impacting the Bronchial Biopsy Devices Market?

AI-assisted technologies are being developed to support lesion identification, image analysis, navigation and procedural planning during bronchoscopic biopsy. Compared to other surgical methods, the robotic system allows precise control, which is essential, especially when the lesion is hard to locate. In addition to enhancing the physician diagnostic capabilities, the ability of patient treatment and management is also impacted positively by AI integration in the robotic system to add further value to these biopsies. They use AI and computer-assisted systems can support functions such as image analysis, lesion identification, navigation and procedural planning, depending on the technology. Robotic and AI-assisted technologies are being developed to improve procedural navigation, visualization and consistency while supporting clinician decision-making.

• In April 2022, the MicroPort Trans-bronchial Surgical Robot, a robotic-assisted bronchoscopy navigation system jointly developed by Shanghai MicroPort MedBot (Group) Co., Ltd., was used in a robot-assisted trans-bronchial biopsy for lung nodules. It offers a system to perform lung disease treatment because it integrates all the intelligent support for the operation, including preoperative planning, respiratory compensation, and intraoperative surgery.

Bronchial Biopsy Devices Market Growth Factor

• Rising incidence of respiratory diseases: The burden of lung cancer and other pulmonary disorders is increasing demand for more precise diagnostic approaches; however, the need for biopsy varies by disease and clinical presentation.
• Aging population: The average global population is aging, and as people age, they are more likely to have respiratory diseases that require diagnostic or therapeutic procedures that require biopsy devices.
• Improved healthcare infrastructure: Rising healthcare infrastructure and the development of technologies in developing nations are aiding in the availability of various complicated medical devices, such as bronchial biopsy tools, that are helping the growth of the bronchial biopsy devices market.
• Government and insurance coverage: As more governments and insurance companies recognize the importance of covering respiratory diseases with treatment and diagnostic procedures, bronchial biopsy devices are becoming available to a new population base.

Market Outlook

• Industry Growth Overview: The bronchial biopsy devices market is expanding rapidly due to rising prevalence of respiratory diseases, increasing demand for minimally invasive diagnostic procedures, and technological advancements in biopsy tools. The growing adoption of flexible, precise devices for early detection of lung disease is driving global market growth.
• Global Expansion: The market is growing worldwide because of increasing cases of lung cancer, chronic obstructive pulmonary disease (COPD), and other respiratory disorders, along with rising awareness about early diagnosis. Emerging regions offer significant opportunities as healthcare infrastructure improves, awareness increases, and adoption of advanced diagnostic technologies accelerates.

Market Scope

Market Dynamics

Driver

Rising incidence of respiratory diseases

Lung cancer continues to become one of the most prevalent types of cancer, and the incidence rate is still rising. Long-term respiratory diseases include chronic obstructive pulmonary disease (COPD), lung cancer, asthma, and interstitial lung disease. Such an increase in respiratory diseases has put more demand for higher and more accurate methods of diagnosis. The leading factors that may have resulted in this rise include increased environmental pollution, smoking, working conditions, and demographic factors. Bronchial biopsy devices facilitate accurate diagnosis early enough for intervention. Lung ailments, including COPD, asthma, and lung malignancy, are progressively being realized in the global populace. The growing operation of bronchial biopsies for diagnosing lung cancer and related conditions.

• The GLOBOCAN 2022 database reveals that lung cancer was the most common cancer identified in 2022, with almost 2.5 million people diagnosed, or one in eight cancers identified globally (12.4% of all cancers globally).

Restraints

Cost constraints

The growth of the bronchial biopsy devices market is limited by high production and purchasing costs, especially for devices that are equipped with the latest technologies. These advanced devices are expensive to develop. The maintenance, training, and other operational costs of these advanced biopsy devices also augment the overall medical care expenses. Many of these devices are costly, putting a financial burden on both healthcare centers and patients to acquire the diagnostic tools that are needed to improve the generation and application of diagnostic procedures.

Opportunity

Rising demand for minimally invasive device

Innovations in bronchial biopsy devices are making processes less invasive, which aids both patients and healthcare providers. Further specific instruments and techniques lessen patient discomfort and recovery times. The development of EBUS-TBNA, radial bronchoscopy, cryobiopsy and robotic bronchoscopy is expanding the range of minimally invasive approaches available for selected pulmonary lesions.

Segment Insights

Product Insights

In the bronchial biopsy devices market, the transbronchial needle aspiration (TBNA) needles segment held the dominating share in 2025. Transbronchial needle aspiration is the method of taking tissue through a needle, which passes through the bronchial wall. It is used to obtain tissue from lung or hilar/mediastinal lesions that are near the endobronchial tree. The development of this segment can be attributed to the advantages of EBUS-TBNA over conventional TBNA and other biopsy methods like mediastinoscopy. Transbronchial needle aspiration (EBUS-TBNA) is a technique that integrates bronchoscopy with ultrasonography, where biopsy is done using a thin needle in real-time visualization of the airway, mediastinum, and lungs.

• In September 2023, Broncus Medical released the new BioStar Transbronchial Aspiration Needle (TBNA), suitable for minimally invasive diagnostics. Medical experts can use the new needle to take accurate tissue samples and quality specimens essential for diagnosing and staging lung cancer. The needle can seamlessly incorporate with endobronchial ultrasound bronchoscopy (EBUS) procedures, improving clinical outcomes and patient care.

The biopsy forceps product segment is expected to grow at a notable rate in the bronchial biopsy devices market during the forecast period. The Biopsy Forceps consists of the manufacturing and sales of tools that are used to biopsy tissues and remove them for diagnosis, especially in instances of cancer as well as other diseases. These are crucial in an ailment diagnosis, as they ensure accuracy and efficiency in sampling. The market comprises various types of forceps, jaws, and needles depending on the diseases/health conditions and procedural requirements. The developments in the biopsy forceps, including accuracy and the ability to perform less invasive biopsies, continue to increase the use of biopsies among healthcare providers.

• In July 2024, Boston Scientific Corporation introduced the United States launching of a new model of its Radial Jaw Single Use Biopsy Forceps with more jaw volume and an enhanced jaw design related to the market-leading Radial Jaw 3 Forceps. Radial Jaw 4 Forceps are intended to allow the collection of large-high-quality tissue specimens without the necessity to use large channel therapeutic endoscopes.

Region Insights

What is the U.S. Bronchial Biopsy Devices Market Size?

The U.S. bronchial biopsy devices market size is exhibited at USD 223 million in 2026 and is projected to be worth around USD 432 million by 2035, growing at a CAGR of 7.62% from 2026 to 2035.

North America dominated the bronchial biopsy devices market with the largest market share in 2025. The market is driven by technological advancements, an effectively developed healthcare system, a high prevalence of chronic diseases, and a growing population of geriatrics. High healthcare expenditure, established reimbursement systems, advanced clinical infrastructure and substantial investment in medical technology support adoption in North America.

• According to the American Cancer Society's estimates for lung cancer in the U.S. for 2026, there will be approximately 229,410 new cases of lung cancer, including 110,910 cases among men and 118,500 among women. Approximately 124,990 deaths from lung cancer are expected, including 63,040 among men and 61,950 among women.

What Makes Europe a Notably Growing Area in the Bronchial Biopsy Devices Market?

Europe is a notably growing region in the market due to the high prevalence of respiratory diseases, including lung cancer and chronic obstructive pulmonary disease (COPD), which drives demand for advanced diagnostic tools. Strong healthcare infrastructure, widespread availability of skilled pulmonologists, and supportive regulatory frameworks facilitate the adoption of minimally invasive biopsy technologies. Additionally, ongoing investments in research and development by leading medical device companies are accelerating innovation and expanding the market across hospitals and specialty clinics in the region.

Germany has established expertise in advanced bronchoscopic and cryobiopsy techniques, supported by clinical research and specialist centers involved in the development and application of . German institutions have contributed to research on cryobiopsy for the diagnosis of interstitial and other pulmonary diseatransbronchial lung cryobiopsyses, while European Respiratory Society guidelines recognize transbronchial lung cryobiopsy as an established tissue-sampling approach in selected patients with interstitial lung disease.

Asia Pacific Emerges as the Fastest-Growing Market for Bronchial Biopsy Devices

Asia Pacific is expected to grow at the fastest rate in the bronchial biopsy devices market during the forecast period. A prominent upsurge in respiratory conditions, including asthma, COPD, and lung cancer. Moreover, there is an increasing prominence on health campaigns intended to grow awareness of respiratory diseases and the importance of regular health check-ups. These initiatives are expected to increase the usage of bronchial biopsy procedures for early diagnosis and treatment of respiratory diseases. This increasing prevalence of the diseases is anticipated to drive the need for better diagnosis techniques, including bronchial biopsy equipment.

Value Chain Analysis

• Raw Material Sourcing
  High-quality metals, polymers, and biocompatible materials are sourced to manufacture safe and reliable biopsy devices.
  Key Players: Medtronic, Olympus Corporation, Boston Scientific
• Device Manufacturing
  Raw materials are processed and assembled into bronchial biopsy tools, including forceps, brushes, needles, and cryoprobes, ensuring precision and safety.
  Key Players: Boston Scientific, Olympus Corporation, Medtronic
• Distribution & Logistics
  Finished devices are distributed through medical distributors, hospitals, and healthcare networks to reach clinics, diagnostic centers, and hospitals worldwide.
  Key Players: Cardinal Health, McKesson Corporation, Medline Industries
• Healthcare Provider & End-Use Application
  Hospitals, pulmonology clinics, and diagnostic centers utilize these devices for early detection and diagnosis of lung diseases like cancer and COPD.
  End Users: Mayo Clinic, Cleveland Clinic, Charite

Bronchial Biopsy Devices Market Companies

• CONMED Corporation: CONMED offers bronchoscopic biopsy forceps, including its Precisor Broncho line of single-use flexible endoscopic biopsy forceps.
• Medtronic: Provides advanced bronchial biopsy devices.
• Boston Scientific Corporation: Offers a range of bronchial biopsy devices, including Acro-Cut biopsy forceps and CryoBalloon devices for improved lung tissue sampling and cancer diagnosis.

Other Major Key Players

• Olympus Corporation
• Becton, Dickinson and Company (BD)
• Cook Medical
• Telemed Systems, Inc.
• HOBBS MEDICAL INC
• Argon Medical Devices (WEIGAO GROUP)
• Horizons International Corp.
• Erbe Elektromedizin GmbH

Latest Announcement by Industry Leader

• In October 2024, Cook County Health invited hosted Cook County Board President Toni Preckwinkle to celebrate the launch of the Intuitive Surgical ION Navigational Bronchoscopy platform in John H. Stroger, Jr. Hospital in Chicago.

• The Ion platform is designed to facilitate navigational bronchoscopy and minimally invasive access to peripheral lung lesions. The technology is intended to support minimally invasive bronchoscopic access to peripheral lung lesions for diagnostic procedures.

Recent Developments

• In October 2024, Invenio Imaging announced that the FDA had granted Breakthrough Device Designation to its NIO Lung Cancer Reveal image-analysis module, designed to assist physicians in evaluating bronchoscopic lung forceps biopsy specimens.
• In October 2025, Intuitive Surgical received FDA clearance for new software upgrades for its Ion robotic bronchoscopy system, improving minimally invasive lung biopsies with accurate location and shape information through fiber optic technology.
  (Source: massdevice.com )
• In May 2023, Argon Medical Devices, Interventional solutions for Radiology, surgery intervention, cardiology, and oncology, announced the release of the SuperCore Advantage Semi-Autocused biopsy device as the latest addition to their soft tissue biopsy devices in the United States market.
• In September 2022, Serpex Medical announced FDA 510(k) clearance for Compass Steerable Needles, designed to facilitate access to difficult-to-reach lesions, including lung nodules.

Segments Covered in the Report

By Product

• Biopsy Forceps
• Durability
• Disposable
• Reusable
• Transbronchial Needle Aspiration (TBNA) Needles
• Conventional
• EBUS-TBNA
• Cytology Brushes
• Cryobiopsy Devices (Cryoprobes)
• Durability
• Disposable
• Reusable

By Geography

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East and Africa